Ambrosia Biosciences Announces Preclinical Data Supporting Differentiated Profile of AMB-702, its Novel Small Molecule GLP-1 Receptor Agonist Development Candidate

AMB-702 demonstrates superior target coverage and efficacy in lean non-human primates The dataset was shared as part of a poster presentation at the American Diabetes Association's (ADA) 86th Scientific Sessions BOULDER, Colo., June 5, 2026 /PRNewswire/ -- Ambrosia Biosciences Inc....